The company’s first-in-class small molecule imipridone, ONC201, showed strong efficacy results in two early-stage clinical trials of 71 pediatric patients with H3K27M-mutant diffuse midline gliomas.
DURHAM - Mike Andriole, a longtime veteran executive at Eli Lilly, is the new CEO at Durham-based pharmaceutical firm Chimerix. Andriole had been chief business officer and chief financial officer at the company. He replaces Mike Sherman, who retired as CEO and is now chair of the company's board. “I have worked closely with Mike